NCT05503511View on ClinicalTrials.gov

Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

March 17, 2023

Study Completion Date

March 30, 2023

Conditions
EpilepsyAlzheimer DiseaseEpilepsy Intractable
Interventions
DRUG

NPT 2042 (bumetanide analog) or Matching Placebo

Soft gelatin capsules

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors
All Listed Sponsors
lead

NeuroPro Therapeutics, Inc.

INDUSTRY

NCT05503511 - Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects | Biotech Hunter | Biotech Hunter